Anatabine does not affect brain astrogliosis in EAE mice.

<p>Representative 40X microscopic fields revealing GFAP immunopositive astrocytes in the cortex, hippocampus and medulla of control, EAE placebo and EAE anatabine treated mice are shown. The histogram represents the average amount of GFAP burden observed in the cortex, hippocampus and medulla of control, EAE placebo and EAE anatabine treated mice. ANOVA shows statistically significant main effect of EAE (P<0.002) and of the area of the brain examined (P<0.002) but no significant main effect of anatabine (P = 0.646) on GFAP burden. Post-hoc analyses reveal statistically significant differences in GFAP burden in the cortex between EAE placebo and control mice (P<0.003) and in the medulla between EAE placebo and control mice (P<0.003).